Iv Therapy Articles & Analysis
7 news found
SeValent is designed to enable intravenous (IV)-only therapies to now be delivered subcutaneously in a controlled manner for use in the home setting. ...
Bexson’s Chief Executive Officer, Gregg Peterson, and Chief Scientific Officer, Jeffrey Becker, are scheduled to present on Thursday, September 22nd, 2022 in New York City, NY and will discuss various new and innovative therapies for the treatment of mental health. Management will be participating in investor one-on-one meetings while in attendance. ...
In the EU it is indicated for symptomatic chronic HF in adult patients with reduced ejection fraction who are stabilized after a recent decompensation event requiring IV therapy. “Vericiguat is currently approved in several countries for heart failure patients who have recently experienced a worsening event. ...
ByBayer AG
The presentation is entitled “STACT: A Novel Therapeutic Platform that Delivers Immunomodulatory Payloads to Tumor-Resident Myeloid Cells After IV Dosing and Demonstrates Potent Anti-Tumor Efficacy in Preclinical Studies”. ...
Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment. See Instructions for Use for complete indications, contraindications, warnings, precautions, and adverse events. ...
Stem Cell Inc, a leader in regenerative medicine products and services, today announced its three partially owned Florida-based clinics have expanded their menu of services to help meet the growing market demand and patient needs for regenerative therapies. In addition to continuing to offer targeted stem cell therapies of all kinds — bone marrow, adipose, ...
Braun Medical Inc., a leader in infusion therapy and pain management. Intravenous (IV) therapy plays a central role in patient care with as many as 90 percent of hospital patients receiving a peripheral IV catheter as part of their treatment plan. ...